title: Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times.
abstract: This study was carried out to evaluate the association between selegiline use and Parkinson's disease (PD) progression in a clinical sample by evaluating modified Hoehn and Yahr Stage (H&Y) stage transition times. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Cox regression analysis was used to examine the association between baseline variables and H&Y stage transition times. In multi-variate Cox regression analysis, patients who were of younger age, shorter PD duration, lower Unified Parkinson's Disease Rating Scale (UPDRS) motor scores, on selegiline treatment (≥ 3 years) and not on COMT inhibitors were associated with longer transition times from stage 2-2.5. Patients who were treated with selegiline (≥ 3 years) and not on COMT inhibitors experienced longer transition times from stage 2.5-3. In conclusion, selegiline use for 3 years or more in early PD was associated with a slower progression of PD as evaluated by H&Y transition times.
authors.affiliation: Department of Pharmacy, National University of Singapore, Republic of Singapore.
authors.forename: Y J
authors.initials: YJ
authors.lastname: Zhao
authors.forename: H L
authors.initials: HL
authors.lastname: Wee
authors.forename: W L
authors.initials: WL
authors.lastname: Au
authors.forename: S H
authors.initials: SH
authors.lastname: Seah
authors.forename: N
authors.initials: N
authors.lastname: Luo
authors.forename: S C
authors.initials: SC
authors.lastname: Li
authors.forename: L C S
authors.initials: LC
authors.lastname: Tan
mesh_terms: D000368:Aged; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology*; D016016:Proportional Hazards Models; D011569:Psychiatric Status Rating Scales; D012642:Selegiline / Q000627:therapeutic use*
chemical_list: D018696:Neuroprotective Agents; D012642:Selegiline